Jason Fredette
Investor Relations Contact chez MERSANA THERAPEUTICS, INC.
Profil
Jason Fredette is currently working as an Investor Relation Contact at Mersana Therapeutics, Inc. He previously held positions as Managing Director-Corporate Communications at American Superconductor Corp.
from 2010 to 2011, Director-Investor Relations at REIT Management & Research LLC, Senior Director-Investor Relations at Chiasma, Inc. from 2015 to 2016, Director-Investor Relations at Office Properties Income Trust, Director-Investor Relations at Select Income REIT, Head-Investor Relations at Selecta Biosciences, Inc., Vice President-Investor Relations at Epizyme, Inc., and Head-Investor Relations at Axcella Health, Inc.
Postes actifs de Jason Fredette
Sociétés | Poste | Début |
---|---|---|
MERSANA THERAPEUTICS, INC. | Investor Relations Contact | - |
Anciens postes connus de Jason Fredette
Sociétés | Poste | Fin |
---|---|---|
CHIASMA, INC. | Investor Relations Contact | 01/01/2016 |
AXCA HEALPAR | Investor Relations Contact | - |
EPIZYME, INC. | Investor Relations Contact | - |
CARTESIAN THERAPEUTICS, INC. | Investor Relations Contact | - |
SELECT INCOME REIT | Investor Relations Contact | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
AMERICAN SUPERCONDUCTOR CORPORATION | Producer Manufacturing |
OFFICE PROPERTIES INCOME TRUST | Finance |
AXCA HEALPAR | Health Technology |
MERSANA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
REIT Management & Research LLC
REIT Management & Research LLC Real Estate Investment TrustsFinance REIT Management & Research LLC provides real estate services. It manages real estate funds for its clients. The company was founded by Barry Michael Portnoy in 1986 and is headquartered in Newton, MA. | Finance |
Select Income REIT
Select Income REIT Real Estate Investment TrustsFinance Select Income REIT operates as a real estate investment trust which owns and invests in single tenant leased properties. Its portfolio includes office and industrial properties as well as leasable land parcels and easements. The company was founded on December 19, 2011 and is headquartered in Newton, MA. | Finance |
Chiasma, Inc.
Chiasma, Inc. Pharmaceuticals: MajorHealth Technology Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Newton Center, MA. | Health Technology |
Selecta Biosciences, Inc.
Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |